MercadoLibre Q4 Results: Don’t Worry (NASDAQ:MELI)

Leila Melhado Introduction In this article, we will be looking at Latin American giant MercadoLibre, Inc.’s (NASDAQ:MELI) recent Q4 earnings release. The fourth quarter typically is the strongest for companies operating in the retail industry. But at least at first glance, the results and the stock price action after the earnings were released might have…

Read More

The Federal Reserve’s Worry List: 5 Concerns

manassanant pamai Today was the day that most believed the Fed would pivot, lowering interest rates by reinstating Quantitative Easing (QE). Recent stock market gains reflect this belief. S&P But few have considered the long-term consequences of the Fed’s actions and the predicament in which it finds itself. It’s not as easy as simply turning…

Read More

Aritzia Stock: Why Fashion Risk Doesn’t Worry Me (TSX:ATZ:CA)

miromiro/iStock Editorial via Getty Images 2023 was a perfect storm of negative events for Aritzia Inc. (TSX:ATZ:CA) (OTCPK:ATZAF): downward guidance, choppy store traffic, inventory buildup, discounting, product cost inflation, and temporary warehousing costs have led to terrible quarters in FY’24: Aritzia EPS (Company Filings) While all of these issues have contributed to the negative outlook,…

Read More

Growth And Inflation Update: Not Much To Worry About

Urupong The big news this week—though widely anticipated—was the 4.9% annualized growth of the economy in the third quarter. Analysts still infected by Phillips Curve thinking worried that a strong economy would encourage the Fed to keep rates “higher for longer,” thus posing the risk of a recession next year. (Note: economic growth does not…

Read More

Coca-Cola’s Q3: Impressive Results, Don’t Worry About Ozempic (NYSE:KO)

karandaev Investment Perspective: Valuation and Growth Post Stock Drop While Coca-Cola’s (NYSE:KO) shares are off almost 14% since their highs earlier this year, they offer a tempting entry point for investors scouting for a top-tier firm with an impressive growth history. Even with short-term challenges such as currency fluctuations and GLP-1 drug-related apprehensions (drugs like…

Read More